Cambridge Consultants “invaluable” in deal says Consort Medical

By Staff Reporter

- Last updated on GMT

Related tags Contract Pharmaceutical drug

Cambridge Consultants (CC) says experience developing auto-injector technologies was critical to its contract appraisal work during Consort Medical’s £16.8m (€11.5m) takeover of The Medical House (TMH).

The UK consulting group was called in by Consort to perform an independent assessment of MH’s auto-injector and needle-free device technologies, specifically to determine if it can be used to delivery biopharmaceuticals.

Consort said that CC’s experience of the design and development of drug delivery devices, particularly injection devices, and record in providing technical due diligence and consulting services had won it the contract.

Consort CEO John Glenn said: “Cambridge Consultants [provided] a comprehensive risk assessed technical appraisal of The Medical House’s technology against demanding time constraints.

“Their deep understanding, both of the technology and its commercial viability, has proved to be invaluable in this transaction, bringing significant value to the deal and minimising our exposure​.”

“A compelling delivery solution”

TMH, headquartered in Sheffield in the UK, has become part of Consort’s Bespack division which makes delivery technologies for inhaled drugs on a contractual basis, particularly for the rapidly expanding metered-dose inhalation market.

Commenting on his firm’s new acqusitrion, Glenn said: “The Medical House will [bring] new expertise in the design of auto-injectors, an exciting and fast-growing self-injection technology driven by the significant increase in use of injectable biologic drugs.

Late year TMH’s ASITM Autoinjector Technology was granted a US patent, winning the firm licensing agreements with a number of firm including Dr Reddy’s, Stallergenes and contract manufacturing organisation (CMO) Catalent.

According to Glenn, this technology, as well as others in TMH’s development pipeline, combined with Bespack’s manufacturing capacity “will offer an increasingly compelling solution to the pharmaceutical industry​.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us


View more